MSOR7 Presentation Time: 5:30 PM

Abstract

Purpose

High-dose-rate interstitial brachytherapy (HDR-IBT) is a favored treatment option over partial penectomy in patients with T1-T2 stage penile carcinoma due to its organ preservation capability. There are limited studies on HDR-IBT in the literature. We analyzed the data of patients of early-stage penile cancer treated with HDR-IBT alone at our center.

Methods and Materials

Between April 2010 and March 2019, 32 patients with T1-T2 stage penile carcinoma were treated with HDR-IBT at our center. Size of the primary lesion ranged from 1.5 cm to 4.0 cm. A free hand implant was performed using plastic catheters in 2-4 planes. The prescription dose of HDR-IBT was 42-51 Gy in 14-17 fractions (twice a day fractionation schedule). Patients were followed up regularly for assessment of local control, survival, toxicity and sexual function.

Results

At a median follow up of 52 months, 6 patients developed recurrent disease at loco-regional site. The 5-year overall survival (OS) was 81% with penis preservation rate (PPR) of 85%. Meatal stenosis was the commonest long-term complication observed in 16 patients. Fifteen of them were managed by frequent urethral dilatations and one patient required temporary suprapubic cystostomy. Eighteen patients had satisfactory sexual function status at the last follow up visit.

Conclusions

The long-term results of our study have demonstrated excellent local control rate and acceptable toxicity with HDR-IBT in patients with T1-2 stage penile carcinoma.